Morningstar Gives AJJ 4 Stars — 75% 3Y Revenue Growth

SG Visual Research
03-31
$AJJ Medtech(584.SI)$  

One chart on AJJ Medtech (SGX: 584).

Morningstar’s quantitative model currently shows 4-Star, ~32% undervaluation, 75%

3Y revenue growth, and a Small Growth classification.

For a micro-cap name, the key point is that AJJ is starting to show up on the market’s

small-growth medtech radar.

@Tiger_SG @新加坡交易所集团 @Daily_Discussion 


US-Iran Conflict | Would Hormuz Blockade Escalate Oil to $120?
After a 21-hour marathon negotiation, the U.S. and Iran moved from “disagreement” straight to a complete breakdown. President Trump announced a U.S.-led blockade of the Strait of Hormuz, a move that has shattered all of the market’s pricing assumptions over the past week. If the U.S. blockade holds through April, will the Fed be forced into a "Hawkish Pivot" that resets Nasdaq valuations? In the clash between Trump’s "Execution Strategy" and Iran’s "Time-Wasting Strategy," who blinks first before the $120 threshold?
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment